Search results for "Amy"

showing 10 items of 1486 documents

Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity

2012

Human apolipoprotein A-I (apoA-I)-derived amyloidosis can present with either wild-type (Wt) protein deposits in atherosclerotic plaques or as a hereditary form in which apoA-I variants deposit causing multiple organ failure. More than 15 single amino acid replacement amyloidogenic apoA-I variants have been described, but the molecular mechanisms involved in amyloid-associated pathology remain largely unknown. Here, we have investigated by fluorescence and biochemical approaches the stabilities and propensities to aggregate of two disease-associated apoA-I variants, apoA-IGly26Arg, associated with polyneuropathy and kidney dysfunction, and apoA-ILys107-0, implicated in amyloidosis in severe…

ProteomicsProtein Foldinglcsh:MedicineProtein aggregationpolymyxinsBiochemistryProtein Structure SecondaryMiceProtein structureneutrophilsMolecular Cell Biologypolycyclic compoundslcsh:ScienceCellular Stress ResponsesMultidisciplinaryProtein StabilityAmyloidosisCiencias QuímicasfluorescenseCell biologymacrophagesBiochemistryToxicityMedicineProtein foldinglipids (amino acids peptides and proteins)medicine.symptomPolyneuropathyResearch ArticleProtein StructureMedicinaLipoproteinsImmunologyBiophysicsInflammationAmyloidogenic ProteinsBiologyProtein ChemistryMicrobiologyCell Lineprotein aggregationmacrophage activationmedicineAnimalsHumansoligomersProtein InteractionsBiologyInflammationamyloidosisApolipoprotein A-IMacrophageslcsh:RImmunityProteinsnutritional and metabolic diseasesmedicine.diseaseApolipoproteinsAmino Acid SubstitutionCell cultureinflammationCiencias Médicaslcsh:QClinical ImmunologyMutant ProteinspolyneuropathyProtein Multimerization
researchProduct

Differential proteomic analysis reveals novel links between primary metabolism and antibiotic production in Amycolatopsis balhimycina.

2010

A differential proteomic analysis, based on 2-DE and MS procedures, was performed on Amycolatopsis balhimycina DSM5908, the actinomycete producing the vancomycin-like antibiotic balhimycin. A comparison of proteomic profiles before and during balhimycin production characterized differentially and constitutively expressed protein isoforms, which were associated to 203 ORFs in the A. balhimycina genome. These data, providing insights on the major metabolic pathways/molecular processes operating in this organism, were used to compile 2-DE reference maps covering 3-10, 4-7 and 4.5-5.5 pH gradients available over the World Wide Web as interactive web pages (http://www.unipa.it/ampuglia/Abal-prot…

ProteomicsProteomeAmycolatopsisBiologyProteomicsSettore BIO/19 - Microbiologia GeneraleBiochemistryMass SpectrometryFungal Proteinschemistry.chemical_compoundBiosynthesisVancomycinActinomycetalesProtein biosynthesisCluster AnalysisElectrophoresis Gel Two-Dimensionalglycopeptide antibioticMolecular BiologyGenechemistry.chemical_classificationGene Expression Profiling2-DE reference mapprimary and secondary metabolismMetabolismHydrogen-Ion ConcentrationAmycolatopsis balhimycinabiology.organism_classificationAnti-Bacterial AgentsAmino acidMetabolic pathwaychemistryBiochemistrygene expressionMetabolic Networks and Pathways
researchProduct

The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin β and ADAM10

2012

The in vivo roles of meprin metalloproteases in pathophysiological conditions remain elusive. Substrates define protease roles. Therefore, to identify natural substrates for human meprin α and β we employed TAILS (terminal amine isotopic labeling of substrates), a proteomics approach that enriches for N-terminal peptides of proteins and cleavage fragments. Of the 151 new extracellular substrates we identified, it was notable that ADAM10 (a disintegrin and metalloprotease domain-containing protein 10)—the constitutive α-secretase—is activated by meprin β through cleavage of the propeptide. To validate this cleavage event, we expressed recombinant proADAM10 and after preincubation with meprin…

Proteomicsalpha-2-HS-Glycoproteinmedicine.medical_treatmentADAM10ADAM10 ProteinMice0302 clinical medicine610 Medicine & healthMice KnockoutExtracellular Matrix Proteins0303 health sciencesMetalloproteinaseDegradomeMetalloendopeptidasesMeprinADAM10Terminal amine isotopic labeling of substratesADAM ProteinsElafinBiochemistryTAILSCytokinesMolecular MedicineElafinResearch Article610 Medicine & healthBiologyCell Line03 medical and health sciencesCellular and Molecular NeurosciencemedicineDisintegrinAnimalsHumansAmino Acid SequenceCystatin CMolecular Biology030304 developmental biologyPharmacologyProteaseMeprin; ADAM10; Metalloproteases; Proteomics; TAILS; DegradomeMembrane ProteinsCell BiologyADAM ProteinsHEK293 CellsMembrane proteinbiology.proteinMetalloproteases570 Life sciences; biologyAmyloid Precursor Protein SecretasesCaco-2 Cells030217 neurology & neurosurgery
researchProduct

Common Factors in Neurodegeneration: A Meta-Study Revealing Shared Patterns on a Multi-Omics Scale

2020

Neurodegenerative diseases such as Alzheimer&rsquo

Proteomicsamyotrophic lateral sclerosisParkinson's diseaseDatabases FactualProteomeDiseaseComputational biologyBiologyPolymorphism Single NucleotideArticleTranscriptomeImmune systemHuntington's diseaseAlzheimer DiseasemedicineHumansbiochemistryAmyotrophic lateral sclerosislcsh:QH301-705.5GeneAlzheimer’s disease ; multi-omics ; neurodegeneration ; Huntington’s disease ; Parkinson’s disease ; amyotrophic lateral sclerosisNeurodegenerationneurodegenerationNeurodegenerative DiseasesParkinson DiseaseGenomicsGeneral Medicinemulti-omicsmedicine.diseaseImmunity HumoralGene OntologyHuntington Diseaselcsh:Biology (General)Parkinson’s diseaseTranscriptomeAlzheimer’s diseaseGenome-Wide Association StudyHuntington’s disease
researchProduct

Polyanion–tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

2016

Aim: Efficacy of antibiotics in cystic fibrosis (CF) is compromised by the poor penetration through mucus barrier. This work proposes a new ‘nano-into-micro’ approach, used to obtain a combinatorial effect: achieve a sustained delivery of tobramycin and overcome mucus barrier. Methods: Mannitol microparticles (MPs) were loaded with a tobramycin polymeric nanocomplex and characterized in presence of CF artificial mucus. Results & discussion: MPs are able to alter the rheological properties of CF artificial mucus, enhancing drug penetration into it and allowing a prolonged drug release. MPs resulted to be effective in Pseudomonas aeruginosa infections if compared with free tobramycin. Co…

Pseudomonas aeruginosa infectionCystic FibrosisPolymersmedicine.drug_classAntibioticsBiomedical EngineeringMedicine (miscellaneous)Bioengineering02 engineering and technologyDevelopmentBiologySettore BIO/19 - Microbiologia Generalenano into micro strategyCystic fibrosisCell LineNanocompositesMicrobiology03 medical and health sciences0302 clinical medicineAntibiotic resistancePseudomonas aeruginosa InfectionsmedicineTobramycinHumansMannitolPseudomonas InfectionsGeneral Materials ScienceDrug CarriersEpithelial CellsPenetration (firestop)021001 nanoscience & nanotechnologymedicine.diseasePolyelectrolytesMucusAnti-Bacterial AgentsDrug LiberationMucusmicroparticle030228 respiratory systemSettore CHIM/09 - Farmaceutico Tecnologico Applicativocystic fibrosis artificial mucuPseudomonas aeruginosaTobramycinMannitol0210 nano-technologyαβ-poly(N-2-hydroxyethyl)-DL-aspartamidespray dryermedicine.drugNanomedicine
researchProduct

Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

2019

Abstract Sustained pulmonary delivery of tobramycin from microparticles composed of drug/polymer nanocomplexes offers several advantages against traditional delivery methods. Namely, in patients with cystic fibrosis, microparticle delivery can protect the tobramycin being delivered from strong mucoadhesive interactions, thus avoiding effects on its diffusion toward the infection site. Polymeric ion-pair complexes were obtained starting from two synthetic polyanions, through impregnation of their solid dissociated forms with tobramycin in aqueous solution. The structure of these polymeric systems was characterized, and their activities were examined against various biofilm-forming Pseudomona…

Pseudomonas aeruginosa infectionpseudomonas aeruginosa infectionsBiocompatibilityCystic FibrosisαPharmaceutical Science02 engineering and technologymedicine.disease_cause030226 pharmacology & pharmacyCystic fibrosisCell Line03 medical and health sciences0302 clinical medicineIon-pair complexmedicineTobramycinHumansPseudomonas InfectionsMicroparticleαβ-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)β-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)chemistry.chemical_classificationDrug CarriersAqueous solutionPseudomonas aeruginosaBiofilms; Cystic fibrosis artificial mucus (CF-AM); Ion-pair complex; Pseudomonas aeruginosa infections; Tobramycin; α; β-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)BiofilmBiofilmPolymerBiofilms; cystic fibrosis artificial mucus (CF-AM); Ion-pair complex; pseudomonas aeruginosa infections; Tobramycin; αβ-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)021001 nanoscience & nanotechnologymedicine.diseaseAnti-Bacterial AgentsMucuschemistryBiofilmsPseudomonas aeruginosaBiophysicsTobramycinNanoparticlescystic fibrosis artificial mucus (CF-AM)0210 nano-technologyPeptidesmedicine.drug
researchProduct

The amyotrophic lateral sclerosis functional rating scale predicts survival time in amyotrophic lateral sclerosis patients on invasive mechanical ven…

2007

Objective: To determine whether the amyotrophic lateral sclerosis functional rating scale (ALSFRS), which is a validated instrument that assesses the functional status and the disease progression in patients with amyotrophic lateral sclerosis (ALS), predicts hospital length of stay and survival time in ALS patients treated with tracheostomy-intermittent positive-pressure ventilation (TIPPV). Methods: Thirty-three consecutive ALS patients with acute respiratory failure who received therapy with TIPPV were prospectively followed up from their admission to the hospital until death. The association of ALSFRS score at hospital admission with length of hospital stay and survival after TIPPV were …

Pulmonary and Respiratory MedicineArtificial ventilationMalemedicine.medical_specialtymedicine.medical_treatmentCritical Care and Intensive Care MedicineSeverity of Illness Indexlaw.inventionIntermittent Positive-Pressure VentilationlawPredictive Value of TestsInternal medicineSickness Impact ProfileSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyAgedProportional Hazards ModelsMechanical ventilationProportional hazards modelbusiness.industryHazard ratioAmyotrophic Lateral SclerosisLength of StayMiddle AgedPrognosisIntensive care unitSurgeryRespiratory failureAcute DiseaseDisease ProgressionSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular MedicinebusinessRespiratory InsufficiencyChest
researchProduct

Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions

2008

Patients suffering from cystic fibrosis (CF) often need to inhale multiple doses of different nebulizable drugs per day. Patients attempt to shorten the time consuming administration procedure by mixing drug solutions/suspensions for simultaneous inhalation. The objective of this experimental study was to determine whether mixtures of the nebulizer solution dornase alfa (Pulmozyme) with tobramycin nebulizer solutions (TOBI and GERNEBCIN 80 mg) are physico-chemically compatible. Drug combinations were prepared by mixing the content of one respule Pulmozyme with either one respule TOBI or one ampoule GERNEBCIN 80 mg. Test solutions were stored at room temperature and exposed to light. Dornase…

Pulmonary and Respiratory MedicineChemical PhenomenaCystic FibrosisExcipientAmpouleDrug Incompatibilitychemistry.chemical_compoundAdministration InhalationTobramycinDeoxyribonuclease IHumansMedicinePotencyChromatographyInhalationbusiness.industryNebulizers and VaporizersDornase alfaSodium metabisulfiteAnti-Bacterial AgentsDrug CombinationsPharmaceutical SolutionsNebulizerchemistryAnesthesiaPediatrics Perinatology and Child HealthTobramycinbusinessmedicine.drugPediatric Pulmonology
researchProduct

Effect of High-Frequency Oscillations on Cough Peak Flows Generated by Mechanical In-Exsufflation in Medically Stable Subjects With Amyotrophic Later…

2016

BACKGROUND: Mechanically assisted coughing with mechanical in-exsufflation (MI-E) is recommended for noninvasive management of respiratory secretions in amyotrophic lateral sclerosis (ALS). To improve the effectiveness of the technique, a new device combining MI-E with high-frequency oscillations (HFO) has been developed. This work aimed to assess the effect of HFO on the cough peak flow generated by MI-E in medically stable subjects with ALS. METHODS: This was a prospective study that included subjects with ALS in a medically stable condition. Cough peak flow generated by MI-E was measured in 4 situations: without HFO, with HFO during insufflation, with HFO during exsufflation, and with HF…

Pulmonary and Respiratory MedicineInsufflationMalemedicine.medical_treatmentHigh-Frequency VentilationPeak Expiratory Flow RateCritical Care and Intensive Care Medicine03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineMedicineHumansNew deviceProspective StudiesRespiratory systemAmyotrophic lateral sclerosisAgedbusiness.industryHigh-frequency ventilationAmyotrophic Lateral SclerosisInsufflationGeneral MedicineMiddle Agedmedicine.diseaseTreatment Outcome030228 respiratory systemRespiratory failureCoughAnesthesiaFemaleExsufflationbusiness030217 neurology & neurosurgeryRespiratory care
researchProduct

Efficacy of Mechanical Insufflation-Exsufflation in Medically Stable Patients With Amyotrophic Lateral Sclerosis

2004

Objective: To determine under what circumstances the use of mechanical insufflation-exsufflation (MI-E) can generate clinically effective expiratory flows for airway clearance (> 2.7 L/s) for clinically stable patients with amyotrophic lateral sclerosis (ALS). Materials and method: Twenty-six consecutive patients with ALS were studied, 15 with severe bulbar dysfunction. Using a pneumotachograph and with the aid of an oronasal mask, we measured FVC, FEV1, peak cough flow (PCF), maximum insufflation capacity (MIC), PCF generated from a maximum insufflation MIC (PCFMIC), and PCF generated by MI-E (PCFMI-E). MI-E was delivered at 40 cm H2O. Maximum inspiratory pressure (PImax) and maximum expir…

Pulmonary and Respiratory MedicineInsufflationNeuromuscular diseasebusiness.industryCritical Care and Intensive Care Medicinemedicine.diseasePulmonary function testingFEV1/FVC ratioAnesthesiamedicineBreathingExsufflationAmyotrophic lateral sclerosisRespiratory systemCardiology and Cardiovascular MedicinebusinessChest
researchProduct